Kornimate/medical-research-clean huggingface dataset:
mimic muscle volume, central facial palsy severity and dysphagia

Conditions: Facial Paralysis, Central; Stroke

Summary: 70 stroke patients with central facial paralysis will be included and their demographic data will be questioned and facial nerve thickness, depressor labi inferior, depressor anguli oris, buccinator and risorius muscles will be evaluated.

70 stroke patients with central facial paralysis who were included in the rehabilitation program at istanbul physical therapy and rehabilitation training and research hospital will be included and their demographic data such as age, gender, marital status, education level, body mass index, stroke etiologies will be questioned and used with the house-brackmann scale. involvement levels, facial nerve thickness (right/left), depressor labi inferior, depressor anguli oris, buccinator and risorius muscles will be evaluated. the data obtained will be correlated with total dysphagia score and facial disability index.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke and presence of unilateral central facial paralysis, * agreeing to participate in the study, * cognitive competence to understand the test instructions, * presence of communication skills to respond to the test instructions. exclusion criteria: * presence of previous facial paralysis or a neurological disease other than stroke that will cause central paralysis, * bilateral involvement * illiteracy, refusal to participate in the study, * jaw joint problem, * surgical intervention in the facial area that will affect ultrasound measurements, * infected open wound.
effectiveness and safety of small aneurysm coiling trial

Conditions: Aneurysm

Summary: to compare the safety and efficacy of treating small aneurysms with coils specially designed for small aneurysms to historically reported rates of safety and efficacy for the treatment of larger aneurysms.

this is a prospective cohort study whereby patients who undergo endovascular treatment with coils for intracranial aneurysms will be studied for initial procedural and 12-18 month post-treatment outcome. the procedural failure rate (defined above) of treating small aneurysms with specially designed coils will be compared to pre-specified historical occurrences. this evaluation will occur within the framework of "non-inferiority" (i.e. comparable success to coiling of large aneurysms).

Eligibility criteria:
inclusion criteria: * patient presenting with a ruptured or un-ruptured cerebral aneurysm appropriate for endovascular treatment as determined by the neurovascular team (neurosurgeon/neurointerventionalist) * patients between (and including) 18 and 90 years of age. * patient hunt and hess grade 0-3. * where required, patient has given fully informed consent to endovascular coiling procedure. if patient cannot consent for themselves, appropriate written consent has been sought from their surrogate, or from appropriate power of attorney. * aneurysm \< 4mm in maximum diameter. * patient is willing and able to return for clinical evaluation and follow-up imaging evaluation (angiography or mra) at both 6-months and 12-18 months after endovascular treatment. * the aneurysm has not previously been treated (by coiling or clipping). * a three-dimensional angiogram has been performed. * placement of at least one "nano" coil, at, or at least close to the neck of the aneurysm. exclusion criteria: * patient has more than one aneurysm requiring treatment in the current treatment session. if a patient has multiple aneurysms, but only one will be treated at the time of enrollment, they are eligible for the trial. (additional aneurysms may be treated at a later date, and may be treated with any coil type that the operator chooses). * patient has an h\&h score of 4 or 5 after subarachnoid hemorrhage (sah). * medical or surgical co-morbidity such that the patient's life expectancy is less than 1 year. * less than 80% by length of stryker endovascular coils are implanted.
outcomes of second generation laser balloon ablation for atrial fibrillation

Conditions: Atrial Fibrillation; Atrial Fibrillation Paroxysmal; Atrial Fibrillation, Persistent

Summary: the purpose of this study is to collect data on laser ballon (2nd gen) systems for catheter ablation for af, in order to determine the safety and the efficacy of this technique. moreover, the investigators aim to determine the short and long term outcomes of pulmonary vein isolation evaluating arrhythmia recurrence, especially using continuous rhythm monitoring with implantable loop recorders (ilr).

light-af is an observational, multicentric study designed to collect pre-procedural, procedural and follow-up data of consecutive patients that underwent catheter ablation for af with laser ballon (2nd gen system). a number of 3 enrolling centers is estimated with an overall number of about 100 patients. a minimal follow-up of 3 months is required before analyzing clinical outcomes. the data analysis will focus on implant outcomes and early, mid and long-term recurrence of af, evaluated with intracardiac rhythm monitoring.

Eligibility criteria:
inclusion criteria: * age \>/= 18 years * patients with paroxysmal, persistent or long-standing persistent af * patients able to provide written informed consent or have informed consent as provided by a legal representative exclusion criteria: * age \< 18 years * patients unable or unwilling to receive oral anticoagulation
mask ventilation with different face masks during neonatal resuscitation

Conditions: Respiration; Insufficient or Poor, Newborn

Summary: most premature babies have difficulty breathing at birth and need help (what we call resuscitation). the treatment for this is to gently inflate their lungs with a resuscitation device and a facemask. the device commonly used is a t-piece infant resuscitator (which we call the t-piece) and is used at the royal alexandra hospital and all round the world. to gentle inflate an infants lung the clinical team put a face mask around your baby's mouth and nose. the clinical team tries to achieve a good seal between the face and the mask. a problem of mask ventilation is that air can escape between the mask and the face (what we call mask leak). currently, two different types of facemasks ("laerdal mask" or "fisher \& paykel mask") are routinely used in the delivery room at the royal alexandra hospital. the purpose of this study is to find out if one facemask is leaking less between the face and the mask.

we will use a laerdal round mask (laerdal, stavanger, norway) compared to a fisher \& paykel (fp) (fisher \& paykel healthcare, auckland, new zealand) 'round' neonatal resuscitation mask. the two point top hold for laerdal 'round' mask and the rim hold for the fisher \& paykel mask. a respiratory function monitor will be placed between the face mask and the ventilation device. it uses a small (dead space 1 ml) flow sensor to measure gas flow in and out of a face mask. this signal is automatically integrated to provide inspired and expired tidal volume. the difference equals the leak from the face mask. it also calculates respiratory rate and minute ventilation, measures spontaneous inspirations and ventilation pressures. the signals of airway flow, tidal volumes, airway pressure, inspired oxygen concentration, temperature, blood pressure, oxygen saturation, heart rate will be digitised and recorded at 200hz using the spectra physiological recording program (a customised neonatal respiratory physiology program). we will compare the % of mask leak within the two face masks.

Eligibility criteria:
inclusion criteria: * preterm infants \<32 weeks gestation born at the royal alexandra hospital who require resuscitation in the delivery room will be recorded. exclusion criteria: * infants will be excluded from final analysis if they have a congenital abnormality or condition that might have an adverse effect on breathing or ventilation, including: congenital diaphragmatic hernia. infants will also be excluded if their parents refuse to give consent to this study. participants will be included in the first minutes after birth if they require mask ventilation for poor respiratory effort. data will be collected from the hospital chart until discharge at around 40 weeks gestation.
realization of the recommendation for influenza vaccination in pregnant women

Conditions: Coverage Rate of Vaccination for Influenza

Summary: introduction: in 2010, the vaccination recommendations for pregnant women against seasonal influenza were published by the german standing committee on vaccination (stiko). this work deals with the immunization coverage and the influencing factors. method: a cross-sectional study was realized at two level 1 perinatal centers in two german federal states during the influenza saisons 2012/2013 and 2013/2014. pregnant women were interviewed by using a standardized and pre-tested questionnaire covering their knowledge about the influenza vaccination and other factors influencing the vaccination decision. furthermore, data from the vaccination card and the pregnancy record booklet have been evaluated.


Eligibility criteria:
inclusion criteria: * pregnant women older than 18 * vaccination records * signatetd letter of agreement exclusion criteria: * younger than 18
study to evaluate the effect of sorbion sachet s wound dressing

Conditions: Pressure Ulcers

Summary: this is a clinical study to evaluate the effects of sorbion sachet s wound dressing on soft tissue edema and wound bioburden in moderately to highly exuding pressure ulcers.

this study is aimed at the participation of subject with moderately to highly exuding pressure ulcers. each subject is expected to participate for a period of 4 weeks or until reepithelization, which occurs first.

Eligibility criteria:
inclusion criteria: * subject \> 18 years. * subject is attending sw wound care center * subject has a wound not smaller than 1cm2 * subject has a wound not larger than 14cm x 23cm * subject has a moderately to highly exudative pressure ulcer that would be indicated for treatment with sorbion sachet s * subject or subject's legally authorized representative is informed about the trial, understands the nature of the study and provides written informed consent prior to study enrollment. * subject is willing and able to comply with all specified care and visit requirements. exclusion criteria: * subject has a lesion that does not meet the inclusion criteria. * subject has a pressure ulcer that contains areas of undermined tissue. * subject refuses to participate in the study. * subject is participating in another clinical study. * subject already participates in this study with one wound (only one wound per subject is allowed) * subject has known sensitivity to the trial product or any of its compounds. * subject is expected to be non-compliant. * subject uses therapy known to be immunocompromising such as systemic anti cancer drugs and/or systemic corticosteroids. * subject suffers from systemic infectious disease(s) known to negatively influence wound healing, such as aids. * subject's lesion is a primary skin cancer. * subject's lesion is the manifestation of a metastasis. * subject is pregnant.

Keywords: reduction on local soft tissue edema
a medical chart review of patients with x-linked myotubular myopathy (xlmtm)

Conditions: Males With X-linked Myotubular Myopathy (XLMTM)

Summary: this retrospective medical chart review (recensus) of approximately 100 xlmtm patients (with a goal to obtain 50 deceased and 20 living records) will provide further knowledge about the clinical manifestations and recorded medical management of xlmtm and potentially inform the design of future therapeutic intervention studies.


Eligibility criteria:
inclusion criteria: * patient diagnosed with xlmtm resulting from a confirmed mutation in the mtm1 gene, or a combination of xlmtm genetically confirmed family history and muscle biopsy * patient is male * access to available medical records for each patient * signed informed consent by the parent(s) or legal guardians and/or assent by the patient (when applicable), unless the associated irb provides an appropriate consent waiver exclusion criteria: * patient data after participation in an interventional study designed to treat xlmtm (patient data prior to participation in an interventional study may be included)

Keywords: xlmtm
"beverage hydration index" of commercial therapeutic beverages

Conditions: Healthy

Summary: the "beverage hydration index" (bhi) assesses the hydration potential of any consumable fluid relative to water. the bhi is a relatively new metric. our purpose was to assess the bhi of beverages never previously tested, including an amino acid-based oral rehydration solution (aa-ors), a glucose-containing ors (g-ors) and a sports drink (sd) compared to water (control).

the "beverage hydration index" (bhi) was created to assess the degree to which beverages "hydrate", by measuring fluid retention after ingesting a 1 liter bolus and comparing it to water. drinks with carbohydrates and electrolytes would traditionally be expected to score higher on the bhi due to glucose-sodium cotransport at the gut and osmolality approaching isotonicity with blood. one recent study reported that an oral rehydration solution (ors) scored better than water, but a "sports drink" did not. no "optimal" bhi beverage composition has been described, nor has an optimal osmolality. recently, a hypotonic amino acid-based rehydration beverage was developed to take advantage of amino acid-sodium cotransport, thus obviating the need for carbohydrate. however, the bhi of this beverage has not yet been assessed. the purpose of this investigation was to assess the hydration potential of this novel beverage in comparison to a commercially available carbohydrate-containing sports drink and oral rehydration solution.

Eligibility criteria:
inclusion criteria: * healthy male or female * aged 18-35 * bmi 18-27 kg/m2 * no known cardiovascular, renal or metabolic disease * moderately active * moderate alcohol use exclusion criteria: * overweight or obese (bmi \>27 kg/m2) * competitive athletes during competition season * current or former cardiovascular, renal or metabolic disease * habitual consumption of alcohol (\>21 units/week) or regular (\>1/week) high (10 units) intake\* * history of psychiatric illness * actively seeking to gain or lose weight * currently taking prescribed medication * example, a 750 ml bottle of wine at 12% abv contains 0.750 liters \* 12 = 9 units

Keywords: fluid balance dehydration rehydration electrolytes urine
ambulatory surgery of lower extremity varicose vein

Conditions: Varicose Veins

Summary: objective: to retrospectively analyze the results of ambulatory treatment on taiwanese patients with primary varicosities of the lower extremities including the use of endovenous laser, phlebectomy, and sclerotherapy. methods: we routinely used tumescent anesthesia and ultrasound-guided approaches for the application of endovenous laser. vein access was achieved by either a percutaneous or stab wound. the laser power was usually 10 - 20 watts; laser treatment usually was begun from 4-10 cm below the saphenofemoral junction, and stopped around the knee, not over 10 cm below the knee. in the same operation, we used mueller's phlebectomy and/or sclerotherapy if there were prominent branch varicosities. we instructed each patient to walk around immediately after the operation, to go home, and to come back 1-3 days later for follow-up. ultrasound scan and venous function follow-up was scheduled at 1 month, 6 months, 12 months, and then annually.


Eligibility criteria:
inclusion criteria: * all patients with varicose veins who underwent endovenous laser treatment for gsv reflux in our hospital were reviewed exclusion criteria: * poor general health, inability to walk, active inflammation of varicose veins, deep venous occlusion disease, hypercoagulability, pregnancy and breast-feeding.
lenvatinib, tislelizumab combined with ralox regimen haic in advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: to evaluate the efficacy and safety of lenvatinib, tislelizumab combined with ralox regimen haic in advanced hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: 1. 18 years or older. 2. hcc was diagnosed according to the criteria for diagnosis and treatment of primary liver cancer (2022 edition) and american association for the study of liver diseases (aasld) criteria. 3. classified as stage c according to the barcelona clinic liver cancer (bclc) staging system. 4. a dominant mass in theliver with or without extrahepatic oligometastasis, which was defined as up to three metastatic lesions in up to two organs with the largest diameter of≤3 cm. 5. no prior treatment for hcc. 6. at least one measurable target lesion according to modified response evaluation criteria in solid tumors (mrecist). 7. performance status (ps) ecog score ≤1. 8. child-pugh score ≤7. 9. subjects voluntarily participate in this study, and sign the informed consent form, cooperate with the follow-up 10. adequate organ function, defined as: hb ≥ 90 g/dl; neu ≥ 1.5 x 10 \^ 9/l; plt ≥ 75 x 10 \^ 9/l; alb ≥2.8 g/dl; tbil ≤2 times the upper limit of normal; ast and alt ≤ 3 times the upper limit of normal; cre ≤1.5 x upper limit of normal; aptt≤1.5 times the upper limit of normal. exclusion criteria: 1. pathologically confirmed diagnosis of fibrolamellar hcc, sarcomatoid hcc, hepatocellular carcinoma-intrahepatic cholangiocarcinoma (hcc-icc) mixed type; 2. previous liver transplantation; 3. history of other malignancies; 4. previous history of severe mental illness; 5. uncontrollable hepatic encephalopathy, hepatorenal syndrome, ascites, pleural effusion or pericardial effusion; 6. active bleeding or coagulation abnormalities, bleeding tendency or receiving thrombolytic, anticoagulant or antiplatelet therapy; 7. other reasons were judged by the investigator to be unable to enroll.
trial of hemodialysis based exercise for strength improvement study

Conditions: End Stage Renal Disease

Summary: study hypothesis: the combination of aerobic and resistance exercise training will improve walking speed compared to either individual intervention. brief summary: sixty hemodialysis participants who meet inclusion and exclusion criteria will be randomized to 20 weeks of supervised exercise, using either: (i) on-dialysis aerobic exercise using a bike ergometer; (ii) pre-dialysis leg strength training using weights; or (iii) both. the primary outcome is walking speed over 4-metres. secondary outcomes will include: (i) short physical performance battery; (ii) health-related quality of life \[euroqol-5d-5l\]; (iii) dialysis recovery time; (iv) nottingham extended activities of daily living (eadl) index; (v) leg strength; (vi) body composition and anthropometry.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * on hemodialysis minimum of 3 times per week * on hemodialysis \> 3 consecutive months exclusion criteria: * inability to provide consent * inability to walk 4-metres * chest pain with exertion or myocardial infarction in past 6-months * pre-dialysis systolic blood pressure \> 200 mm hg or diastolic bp \> 100 mm hg in past 2-weeks * functional or cardiorespiratory limitations preventing use of cycle ergometer for at least five-minutes or the ability to perform single maximum rep with each of resistance exercises described * joint replacement or lower extremity fracture in previous 6-months * severe cognitive impairment * currently using corticosteroids \>5 mg/day * pre-dialysis serum potassium in previous month less than 3.5 or greater than 6.0 mmol/l. * attending nephrologist feels exercise is medically contraindicated * scheduled living related kidney transplant in next 6 months

Keywords: hemodialysis aerobic exercise resistance training walking speed randomized controlled trial
effect of consumption of post-harvest uv-b treated mushrooms on vitamin d status of healthy adults

Conditions: Vitamin D Deficiency

Summary: this study will investigate whether mushrooms treated with ultraviolet (uv) light to increase their vitamin d2 content are actually a good source of vitamin d when consumed daily with a meal (lunch). the mushrooms will be provided cooked along with a meal which will be a standard, pre-packaged frozen meal. we also hope to learn if the resulting improvement in vitamin d status affects the immune system by decreasing it's level of activation, which may be abnormally elevated in vitamin d deficiency.

volunteers will be asked to consume a standard meal (lunch) containing one serving of mushrooms daily for six weeks (7 days per week). with the meal, they will also need to take one capsule. the capsule will be either a placebo or will contain vitamin d. the purpose of the vitamin d in the capsule is to determine if the vitamin d from the mushrooms is absorbed as well as vitamin d from a capsule. the total dose of vitamin d that volunteers will receive each day from mushrooms and capsule together will always be the same and will be one of three doses: (1) little or no vitamin d (placebo); (2) 400 iu, which is near the current recommended intake and (3) 1,000 iu, which is up to five-fold higher than the current recommended intake, depending on your age. both levels of vitamin d are safe. in addition to consuming the meals and taking the capsules, up to 20 ml (4 teaspoons) of blood will be drawn at three times during the study just before the mushroom-containing lunch is provided: (1) at the beginning of the study before the first meal; (3) after three weeks; (3) at the end of the study. the purpose of the blood draw is to measure vitamin d in your blood and to measure the level of activation of your immune system by measuring markers of immune activation.

Eligibility criteria:
inclusion criteria: * willing to consume a lunch meal 7 days per week for 6 weeks containing mushrooms * willing to stop eating other sources of mushrooms * willing to discontinue taking vitamin d and other dietary supplements * estimated low vitamin d status based on dietary questionnaire, skin reflectance, and sun behavior exclusion criteria: * women who are pregnant or breastfeeding * volunteers with anemia * volunteers with evidence of underlying disease affecting vitamin d metabolism * volunteers taking medications altering vitamin d metabolism

Keywords: vitamin d